Medroxyprogesterone: Clinical Trials

6 trials of Medroxyprogesterone, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 terminated, 1 unknown. 6 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 26Completed 4, Terminated 1, Unknown 1
Phase 31Completed 1

Follow Medroxyprogesterone: new trials by email Literature Review of Medroxyprogesterone trials Research Report on Medroxyprogesterone

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Repurposed Drugs to Improve Haematological Responses in Myelodysplastic Syndromes
Sodium Valproate, Bezafibrate, Medroxyprogesterone, Danazol - Myelodysplastic Syndromes (MDS)
Phase 2UnknownProf. Janet Dunn1202021-12-212023-10-03
Medroxyprogesterone +/- Cyclophosphamide & Methotrexate in Hormone Receptor-Negative Recurrent/Metastatic Breast Cancer
Medroxyprogesterone progesterone acetate (MPA), Medroxyprogesterone with Cyclophosphamide + Methotrexate - Estrogen Receptor-negative Breast Cancer, Progesterone Receptor-negative Breast Cancer
Phase 2CompletedIndiana University302007-07-012023-10-16
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
Laboratory Biomarker Analysis, Medroxyprogesterone, Therapeutic Conventional Surgery - Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Phase 2CompletedGynecologic Oncology Group752004-04-012016-04-11
Hormone Therapy in Preventing Endometrial Cancer in Patients With a Genetic Risk For Hereditary Nonpolyposis Colon Cancer
medroxyprogesterone, ethinyl estradiol, norgestrel - Endometrial Cancer
Phase 2CompletedNational Cancer Institute (NCI)522002-02-012013-05-03
Alzheimer's Disease: Therapeutic Potential of Estrogen
Transdermal estradiol, Medroxyprogesterone, Placebo Patch - Alzheimer Disease
Phase 2 / Phase 3CompletedUniversity of Wisconsin, Madison422001-09-012018-08-23
Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer
medroxyprogesterone - Endometrial Cancer
Phase 2TerminatedGynecologic Oncology Group3601998-11-012013-06-10

Conditions studied

Endometrial Neoplasms (2)  ·  Alzheimer Disease (1)  ·  Breast Neoplasms (1)  ·  Myelodysplastic Syndromes (1)

Sponsors

Gynecologic Oncology Group (2)  ·  Indiana University (1)  ·  National Cancer Institute (NCI) (1)  ·  Prof. Janet Dunn (1)  ·  University of Wisconsin, Madison (1)

Countries

United States (5)  ·  Norway (1)  ·  United Kingdom (1)

Top investigators

Francisco A. R. Garcia, MD, MPH (1)  ·  George L. Mutter, MD (1)  ·  John P. Curtin, MD (1)  ·  Karen Lu (1)  ·  Kathy Miller, MD (1)  ·  Richard Zaino (1)  ·  Richard Zaino, MD (1)  ·  Sanjay Asthana, MD (1)

Results publications

PMID 16400639, PMID 22155796

NIH funding

R01AG017196 (1), U10CA027469 (1)